Acorda Therapeutics | ACOR

Acorda Therapeutics traded at $0.94 this Friday January 27th, decreasing $0.01 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, Acorda Therapeutics lost 50.40 percent. Over the last 12 months, its price fell by 46.89 percent. Looking ahead, we forecast Acorda Therapeutics to be priced at 0.94 by the end of this quarter and at 0.85 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.94
Daily Change
-1.20%
Yearly
-46.89%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 18.57 -0.09 -0.48% -16.01%
Acorda Therapeutics 0.94 -0.01 -1.20% -46.89%
Agios Pharmaceuticals 30.75 0.03 0.10% 2.30%
ALKERMES 29.02 0.52 1.82% 15.71%
Amgen 253.65 -1.23 -0.48% 10.70%
Anika Therapeutics 30.66 -0.79 -2.51% -2.08%
Aptinyx Inc 0.42 0.01 3.58% -86.62%
Arrowhead Research 33.61 0.33 0.99% -32.90%
Biogen 290.08 -1.84 -0.63% 28.80%
BioMarin Pharmaceutical 117.27 0.29 0.25% 36.11%
Cara Therapeutics 12.00 -0.27 -2.20% 8.79%
Clovis Oncology 0.11 -0.001 -0.90% -94.30%
Cytokinetics 43.12 -0.13 -0.30% 36.63%
Enanta Pharmaceuticals 52.02 0.51 0.99% -11.38%
Gilead Sciences 83.70 0.11 0.13% 21.55%
GlaxoSmithKline 1,410.00 4.80 0.34% -15.11%
Halozyme Therapeutics 50.71 -2.57 -4.82% 55.74%
Heron Therapeutics 2.79 0.19 7.31% -65.77%
Insmed 21.69 0.23 1.07% 1.36%
Ligand Pharmaceuticals 70.29 0.57 0.82% -39.79%
MannKind 5.23 -0.08 -1.51% 47.32%
Merck 190.40 -2.10 -1.09% -0.34%
Moderna Inc 189.35 -3.89 -2.01% 18.74%
Neurocrine Biosciences 108.25 -0.13 -0.12% 41.08%
Novartis 82.58 -0.10 -0.12% 4.04%
Pfizer 43.79 -0.46 -1.04% -19.40%
Ultragenyx Pharmaceutical 43.72 -0.42 -0.95% -33.76%
Sanofi 89.61 -0.11 -0.12% -4.93%
Teva Pharmaceutical Industries Ltd 3,459.00 54.00 1.59% 27.17%
Vertex Pharmaceuticals 321.77 0.43 0.13% 32.40%

Indexes Price Day Year
USND 11622 109.30 0.95% -15.60%

Acorda Therapeutics
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.